Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.

WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...

A recently released negative study by Novo Nordisk (NVO) on the differences between its own semaglutide and liraglutide ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

The FDA has issued warnings about the risks of compounded semaglutide. Ren-Fielding and her team often ask visiting ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as ...

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 54.1% in the morning session on continued positive ...